Dutasteride was patented in 1996  and was first described in the scientific literature in 1997.  It was approved by the FDA for the treatment of BPH in November 2001 and was introduced into the . market the following year under the brand name Avodart.  Dutasteride has subsequently been introduced in many other countries as well, including throughout Europe and South America .  The patent protection of dutasteride expired in November 2015 and the drug has since become available in the . in a variety of low-cost generic formulations . 
Drugs can be added and removed from this list by WADA annually, although not all of the banned substances are explicitly named. Caroline Hatton, PhD , a sports anti-doping science consultant, told in a Mar. 12, 2010 email that "A key concept in prohibited lists is that they avoid being finite. Instead of listing all banned drugs one by one, they list entire drug classes and name drugs merely as examples. This is to keep users who took designer drugs from claiming that they didn't break the rules because the drugs they took weren't listed."